News

Together the two companies are projected to generate approximately $136 million dollars in revenue in 2016 and are projecting $156 million in revenue for 2017. F.A.S.T. will retain

The deal, which was signed in June 2016, includes the transfer of Sanofi’s ownership of the €11.4bn Merial animal health business to Boehringer in return for the latter's

The study is enrolling patients with non-small cell lung cancer (NSCLC) who have failed prior therapy.  The trial will begin with a Phase 1 safety component, enrolling up

TetraLogic sold its SMAC mimetic program, including their clinical stage asset birinapant, and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir for a purchase price of $12m payable in

Following a preliminary review of the company's NDA for Xaracoll, filed in October 2016, the FDA concluded that the application was not sufficiently complete to allow for a more

The REACH-1 phase 2 trial is assessing ruxolitinib in combination with corticosteroids It has a primary endpoint defined as overall response rate at day 28 of the single-cohort clinical trial. Some

The Pennsylvania based global pharma rolled out Methylphenidate Hydrochloride extended-release tablets USP, 18mg, 27mg, 36mg and 54mg, which are indicted for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

The brands bought by Zydus Healthcare in the deal are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten which are expected to strengthen the global pharmaceutical group’s portfolio in

Effi-7, an antagonist of the interleukin-7 receptor, is intended to treat patients suffering from invalidating autoimmune pathologies. The deal is inclusive of an upfront payment of €10.25m by